利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

9 条记录 (耗时 0.054 秒)

    Cancer immunotherapy with carrier cells
    7.
    发明授权
    Cancer immunotherapy with carrier cells 失效
    用载体细胞进行癌症免疫治疗

    公开(公告)号：US5674486A

    公开(公告)日：1997-10-07

    申请号：US473123

    申请日：1995-06-06

    申请人： Robert E. Sobol ,  Fred H. Gage ,  Ivor Royston ,  Theodore Friedmann

    发明人： Robert E. Sobol ,  Fred H. Gage ,  Ivor Royston ,  Theodore Friedmann

    IPC分类号： A61K38/19 ,  A61K38/20 ,  A61K39/00 ,  A61K48/00 ,  A61K35/76 ,  C12N5/00

    CPC分类号： A61K38/2013 ,  A61K39/0011 ,  A61K48/00

    摘要： A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to tumor antigens. In one embodiment, autologous fibroblasts genetically modified to secrete at least one cytokine gene product are utilized to immunize the patient in a formulation with tumor antigens at a site other than an active tumor site. In another embodiment, cells genetically modified to express at least one tumor antigen gene product and to secrete at least one cytokine gene product are utilized in a formulation to immunize the patient at a site other than an active tumor site.

    摘要翻译： 描述了一种新的肿瘤免疫治疗方法，其包括导致分泌细胞因子基因产物以刺激患者对肿瘤抗原的免疫应答的细胞的遗传修饰。 在一个实施方案中，利用经遗传修饰以分泌至少一种细胞因子基因产物的自体成纤维细胞在具有肿瘤抗原的制剂中在除活性肿瘤部位之外的部位免疫患者。 在另一个实施方案中，在制剂中利用遗传修饰以表达至少一种肿瘤抗原基因产物并分泌至少一种细胞因子基因产物的细胞，以在除活性肿瘤部位之外的部位免疫患者。

    Lymphokine gene therapy of cancer
    8.
    发明授权
    Lymphokine gene therapy of cancer 失效
    淋巴因子基因治疗癌症

    公开(公告)号：US5681562A

    公开(公告)日：1997-10-28

    申请号：US352990

    申请日：1994-12-09

    申请人： Robert E. Sobol ,  Fred H. Gage ,  Ivor Royston ,  Theodore Friedman ,  Habib Fakhrai

    发明人： Robert E. Sobol ,  Fred H. Gage ,  Ivor Royston ,  Theodore Friedman ,  Habib Fakhrai

    IPC分类号： A61K38/19 ,  A61K38/20 ,  A61K39/00 ,  A61K48/00 ,  C07K14/55 ,  C12N15/85 ,  C12N5/00

    CPC分类号： A61K39/0011 ,  C07K14/55 ,  C12N15/85 ,  A61K38/00 ,  A61K39/00 ,  A61K48/00

    摘要： A novel method of tumor immunotherapy is described comprising the genetic modification of cells resulting in the secretion of cytokine gene products to stimulate a patient's immune response to tumor antigens. In one embodiment, autologous fibroblasts genetically modified to secrete at least one cytokine gene product are utilized to immunize the patient in a formulation with tumor antigens at a site other than an active tumor site. In another embodiment, cells genetically modified to express at least one tumor antigen gene product and to secrete at least one cytokine gene product are utilized in a formulation to immunize the patient at a site other than an active tumor site.

    摘要翻译： 描述了一种新的肿瘤免疫治疗方法，其包括导致分泌细胞因子基因产物以刺激患者对肿瘤抗原的免疫应答的细胞的遗传修饰。 在一个实施方案中，利用经遗传修饰以分泌至少一种细胞因子基因产物的自体成纤维细胞在具有肿瘤抗原的制剂中在除活性肿瘤部位之外的部位免疫患者。 在另一个实施方案中，在制剂中利用遗传修饰以表达至少一种肿瘤抗原基因产物并分泌至少一种细胞因子基因产物的细胞，以在除活性肿瘤部位之外的部位免疫患者。

    Monoclonal antibody methods and compositions specific for single antigens in antigen aggregates
    9.
    发明授权
    Monoclonal antibody methods and compositions specific for single antigens in antigen aggregates 失效
    单克隆抗体方法和抗原聚集体中单抗原特异性的组合物

    公开(公告)号：US4675386A

    公开(公告)日：1987-06-23

    申请号：US495728

    申请日：1983-05-19

    申请人： Ivor Royston ,  John Majda ,  Gayle Yamamoto

    发明人： Ivor Royston ,  John Majda ,  Gayle Yamamoto

    IPC分类号： C07K16/28 ,  A61K39/395 ,  C12N5/00 ,  C12N15/00 ,  C12P21/00

    CPC分类号： C07K16/28 ,  Y10S435/948 ,  Y10S530/808

    摘要： Methods and compositions are provided for producing monoclonal antibodies capable of distinguishing between antigenic aggregates, which are differentiated by one or a small number of antigenic determinants. The method involves immunization of a mammal to produce spleen cells which are fused with a cell line which is stable in vitro. The hybridized cells are then dispensed into culture wells at a density level which encourages the production of one colony per well. Autologous antigenic aggregates are employed for screening to distinguish the antibodies which discriminate between the antigenic aggregates. Particularly, mice are hyperimmunized with a homogeneous population of T-cells, the immunized mice killed and the spleens removed. The spleen cells are fused with mouse myeloma cells and the resulting hybrids plated at a relatively low density in culture wells. Plates containing fewer than 30% hybrid positive wells are found to have primarily one colony per well. The cell supernatants are screened against autologous T- and B-cells and hybrid antibodies which do not bind to the B-cells are specific for T-cells.

    摘要翻译： 提供了用于产生能够区分由一个或少数抗原决定簇分化的抗原性聚集体的单克隆抗体的方法和组合物。 该方法包括免疫哺乳动物以产生与体外稳定的细胞系融合的脾细胞。 然后将杂交的细胞以鼓励每孔产生一个菌落的密度水平分配到培养孔中。 自体抗原聚集体用于筛选以鉴别鉴别抗原聚集体之间的抗体。 特别地，用同样的T细胞群体对小鼠进行超免疫，免疫的小鼠被杀死，脾脏被去除。 将脾细胞与小鼠骨髓瘤细胞融合，并将所得杂交体以相对较低的密度铺在培养孔中。 发现含有少于30％混合阳性井的板块每孔主要有一个菌落。 对自体T细胞和B细胞筛选细胞上清液，并且不结合B细胞的杂交抗体对T细胞是特异性的。